| Year |
Citation |
Score |
| 2023 |
Yashchenko A, Bland SJ, Song CJ, Ahmed UKB, Sharp R, Darby IG, Cordova AM, Smith ME, Lever JM, Li Z, Aloria EJ, Khan S, Maryam B, Liu S, Crowley MR, ... ... Hopp K, et al. controls kidney resident macrophage heterogeneity. Frontiers in Immunology. 14: 1082078. PMID 37256130 DOI: 10.3389/fimmu.2023.1082078 |
0.325 |
|
| 2022 |
Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. Jci Insight. PMID 36422996 DOI: 10.1172/jci.insight.154773 |
0.408 |
|
| 2022 |
Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. Journal of Nephrology. PMID 35867237 DOI: 10.1007/s40620-022-01361-6 |
0.368 |
|
| 2022 |
Meena P, Hopp K. The Enigma of Clinical Heterogeneity Among Autosomal Recessive Polycystic Kidney Disease Siblings: Genotype Versus Other Genomic or Environmental Modifier. Kidney International Reports. 7: 1453-1455. PMID 35812282 DOI: 10.1016/j.ekir.2022.04.092 |
0.343 |
|
| 2022 |
Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. American Journal of Nephrology. 1-9. PMID 35263737 DOI: 10.1159/000522113 |
0.431 |
|
| 2022 |
Song C, Li Z, Ahmed UKB, Bland S, Yashchenko A, Liu S, Aloria E, Lever J, Gonzalez N, Bickel M, Giles C, Georgescu C, Wren J, Lang M, Benveniste E, ... ... Hopp K, et al. A Comprehensive Immune Cell Atlas of Cystic Kidney Disease Reveals the Involvement of Adaptive Immune Cells in Injury-Mediated Cyst Progression in Mice. Journal of the American Society of Nephrology : Jasn. PMID 35110364 DOI: 10.1681/ASN.2021030278 |
0.323 |
|
| 2022 |
Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. American Journal of Physiology. Renal Physiology. 322: F258-F267. PMID 35037466 DOI: 10.1152/ajprenal.00262.2021 |
0.381 |
|
| 2021 |
Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres VE, Hopp K, Harris PC. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1 mouse model of autosomal dominant polycystic kidney disease. Kidney International. PMID 33705824 DOI: 10.1016/j.kint.2021.01.028 |
0.578 |
|
| 2020 |
Atwood DJ, Brown CN, Holditch SJ, Pokhrel D, Thorburn A, Hopp K, Edelstein CL. The effect of trehalose on autophagy-related proteins and cyst growth in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Cellular Signalling. 109760. PMID 32866627 DOI: 10.1016/J.Cellsig.2020.109760 |
0.47 |
|
| 2020 |
Nowak KL, Hopp K. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 32086281 DOI: 10.2215/Cjn.13291019 |
0.449 |
|
| 2019 |
Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, et al. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International. PMID 31874800 DOI: 10.1016/J.Kint.2019.08.038 |
0.639 |
|
| 2019 |
Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Human Molecular Genetics. PMID 31646342 DOI: 10.1093/Hmg/Ddz244 |
0.376 |
|
| 2019 |
Gewin L, Summers ME, Harral JW, Gaskill CF, Nlandu Khodo S, Neelisetty S, Sullivan TM, Hopp K, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM. Inactivation of in Abcg2 Lineage Derived Cells Drives the Appearance of Polycystic Lesions and Fibrosis in the Adult Kidney. American Journal of Physiology. Renal Physiology. PMID 31461347 DOI: 10.1152/Ajprenal.00629.2018 |
0.387 |
|
| 2019 |
Olson RJ, Hopp K, Wells H, Smith JM, Furtado J, Constans MM, Escobar DL, Geurts AM, Torres VE, Harris PC. Synergistic Genetic Interactions between and Result in an ARPKD-Like Phenotype in Murine Models. Journal of the American Society of Nephrology : Jasn. PMID 31427367 DOI: 10.1681/Asn.2019020150 |
0.626 |
|
| 2019 |
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and an mTOR kinase inhibitor (TORKi) in a hypomorphic mouse model of autosomal dominant polycystic kidney disease (ADPKD). American Journal of Physiology. Renal Physiology. PMID 31042058 DOI: 10.1152/Ajprenal.00051.2019 |
0.439 |
|
| 2019 |
Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans MC, Nemenoff RA, Furgeson SB. Inhibition of 5-Lipoxygenase Decreases Renal Fibrosis and Progression of Chronic Kidney Disease. American Journal of Physiology. Renal Physiology. PMID 30649890 DOI: 10.1152/Ajprenal.00262.2018 |
0.485 |
|
| 2018 |
Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8 T cells modulate autosomal dominant polycystic kidney disease progression. Kidney International. PMID 30249452 DOI: 10.1016/J.Kint.2018.06.025 |
0.512 |
|
| 2018 |
Boczek NJ, Hopp K, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW. Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. European Journal of Human Genetics : Ejhg. PMID 30097616 DOI: 10.1038/S41431-018-0222-3 |
0.57 |
|
| 2018 |
Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, et al. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics. PMID 29706351 DOI: 10.1016/J.Ajhg.2018.03.013 |
0.676 |
|
| 2016 |
Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, et al. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. American Journal of Human Genetics. 98: 1193-1207. PMID 27259053 DOI: 10.1016/J.Ajhg.2016.05.004 |
0.67 |
|
| 2016 |
Heyer CM, Sundsbak JL, Abebe KZ, Chapman AB, Torres VE, Grantham JJ, Bae KT, Schrier RW, Perrone RD, Braun WE, Steinman TI, Mrug M, Yu AS, Brosnahan G, Hopp K, et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology : Jasn. PMID 26823553 DOI: 10.1681/Asn.2015050583 |
0.622 |
|
| 2015 |
Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. Journal of the American Society of Nephrology : Jasn. PMID 26538633 DOI: 10.1681/Asn.2015020132 |
0.607 |
|
| 2015 |
Ye H, Wang X, Sussman CR, Hopp K, Irazabal MV, Bakeberg JL, LaRiviere WB, Manganiello VC, Voorhees CV, Zhao H, Harris PC, van Deursen J, Ward CJ, Torres VE. Modulation of Polycystic Kidney Disease Severity by Phosphodiesterase 1 and 3 Subfamilies. Journal of the American Society of Nephrology : Jasn. PMID 26374610 DOI: 10.1681/Asn.2015010057 |
0.553 |
|
| 2015 |
Kline TL, Irazabal MV, Ebrahimi B, Hopp K, Udoji KN, Warner JD, Korfiatis P, Mishra PK, Macura SI, Venkatesh SK, Lerman LO, Harris PC, Torres VE, King BF, Erickson BJ. Utilizing magnetization transfer imaging to investigate tissue remodeling in a murine model of autosomal dominant polycystic kidney disease. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. PMID 25974140 DOI: 10.1002/Mrm.25701 |
0.544 |
|
| 2015 |
Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC. Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. Journal of the American Society of Nephrology : Jasn. PMID 25644115 DOI: 10.1681/Asn.2014070698 |
0.489 |
|
| 2015 |
Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC. Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. The Journal of Clinical Investigation. 125: 607-20. PMID 25574838 DOI: 10.1172/Jci76972 |
0.59 |
|
| 2015 |
Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. American Journal of Physiology. Renal Physiology. 308: F261-6. PMID 25503729 DOI: 10.1152/Ajprenal.00345.2014 |
0.538 |
|
| 2015 |
Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE. Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. Journal of the American Society of Nephrology : Jasn. 26: 39-47. PMID 24994926 DOI: 10.1681/Asn.2013121312 |
0.549 |
|
| 2014 |
Hopp K. Improving HNF1β mutation detection rates: can a weighted score of clinical and familial characteristics help? Kidney International. 86: 882-4. PMID 25360493 DOI: 10.1038/Ki.2014.245 |
0.418 |
|
| 2014 |
Paul BM, Consugar MB, Ryan Lee M, Sundsbak JL, Heyer CM, Rossetti S, Kubly VJ, Hopp K, Torres VE, Coto E, Clementi M, Bogdanova N, de Almeida E, Bichet DG, Harris PC. Evidence of a third ADPKD locus is not supported by re-analysis of designated PKD3 families. Kidney International. 85: 383-92. PMID 23760289 DOI: 10.1038/Ki.2013.227 |
0.584 |
|
| 2013 |
Harris PC, Hopp K. The mutation, a key determinant of phenotype in ADPKD. Journal of the American Society of Nephrology : Jasn. 24: 868-70. PMID 23687354 DOI: 10.1681/Asn.2013040417 |
0.645 |
|
| 2012 |
Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, Rossetti S, Torres VE, Harris PC. Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. The Journal of Clinical Investigation. 122: 4257-73. PMID 23064367 DOI: 10.1172/Jci64313 |
0.662 |
|
| 2012 |
Rossetti S, Hopp K, Sikkink RA, Sundsbak JL, Lee YK, Kubly V, Eckloff BW, Ward CJ, Winearls CG, Torres VE, Harris PC. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. Journal of the American Society of Nephrology : Jasn. 23: 915-33. PMID 22383692 DOI: 10.1681/Asn.2011101032 |
0.598 |
|
| 2011 |
Hopp K, Heyer CM, Hommerding CJ, Henke SA, Sundsbak JL, Patel S, Patel P, Consugar MB, Czarnecki PG, Gliem TJ, Torres VE, Rossetti S, Harris PC. B9D1 is revealed as a novel Meckel syndrome (MKS) gene by targeted exon-enriched next-generation sequencing and deletion analysis. Human Molecular Genetics. 20: 2524-34. PMID 21493627 DOI: 10.1093/Hmg/Ddr151 |
0.579 |
|
| 2010 |
Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, Rudenhed B, Nasr SH, Torres VE, Torra R, Bogdanova N, Harris PC. Incompletely penetrant PKD1 alleles mimic the renal manifestations of ARPKD. Journal of the American Society of Nephrology : Jasn. 21: 1097-102. PMID 20558538 DOI: 10.1681/Asn.2009101070 |
0.67 |
|
| 2009 |
Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, Chauveau D, Rees L, Barratt TM, van't Hoff WG, Niaudet P, Niaudet WP, Torres VE, Harris PC. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney International. 75: 848-55. PMID 19165178 DOI: 10.1038/Ki.2008.686 |
0.671 |
|
| Show low-probability matches. |